NCT05956821View on ClinicalTrials.gov

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

October 1, 2029

Study Completion Date

December 1, 2029

Conditions
Glioblastoma MultiformeAnaplastic AstrocytomaFibrillary AstrocytomasOligodendrogliomaDiffuse Intrinsic Brainstem GliomaDiffuse Intrinsic Pontine GliomaDIPG Brain TumorH3 K27M
Interventions
DRUG

SIACI of cetuximab and bevacizumab

Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2)

Trial Locations (1)

33136

RECRUITING

Jackson Memorial Hospital, Miami

All Listed Sponsors
lead

University of Miami

OTHER